Li H, et al. - Researchers undertook a retrospective and multicenter analysis to investigate the very-low-dose decitabine schedule for the treatment of patients with IPSS intermediate- or high-risk myelodysplastic syndrome (MDS). In the treatment of intermediate- or high-risk MDS, very-low-dose decitabine exhibited relatively good efficacy, good tolerance, and low medical cost. The most suitable candidates for this regimen could be the elderly patients with more than 1 complication or patients with a higher proportion of blast cells.